Zofran Birth Defects Lawsuit MDL Sets First Conference Date

October 30, 2015 – – ZofranLegal.com reports that multidistrict litigation which was established for federally-filed Zofran Birth Defects Lawsuits earlier this month is making preparations to begin. A notice filed just days ago by the U.S. District Court for the District of Massachusetts announced that the first status conference for proceedings regarding MDL No. 2657 will be held on November 17, 2015 at 9:30am.

The Zofran Birth Defect Lawsuits, which continue to mount, share many similar allegations indicating that expectant mothers who used the drug subsequently gave birth to children with defects. The medication, which was never FDA-approved to treat pregnant mothers, but was marketed to this audience, has come under much scrutiny.

Plaintiffs state that had they known the alleged risks of the drug, which they claim manufacturer GlaxoSmithKline purposefully neglected to share, they would have never used the drug to combat nausea associated with morning sickness.

Zofran was approved by the FDA to treat patients experiencing extreme nausea and vomiting after undergoing chemotherapy, radiation, or anesthesia. The product has never been tested for safety on pregnant women.

Attorneys at Monheit Law are currently working to ensure that others who have used Zofran while pregnant, and later gave birth to a child with defects are able to explore their legal rights. The children and parents involved may be entitled to compensation. Monheit Law offers free and confidential consultations for anyone who may want to ask further questions regarding the legal process.

For additional information on this release or to ask questions, please contact Michael Monheit, Esq. at 877-620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60004977